Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

Similar documents
Nucleic Acid Amplification Testing for the Diagnosis of TB

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

TB Laboratory for Nurses

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

TB Update: March 2012

Ken Jost, BA, has the following disclosures to make:

TB NAAT testing at the Los Angeles County Public Health Laboratory

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

TB 101 Disease, Clinical Assessment and Lab Testing

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Performance of Nucleic Acid Amplification Tests for Diagnosis of Tuberculosis in a Large Urban Setting

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Changing TB Isolation Practices: Consensus Statement Concerning the Incorporation of Molecular Testing

Clinical Impact of Nucleic Acid Amplification Testing in the Diagnosis of Mycobacterium Tuberculosis: A 10-Year Longitudinal Study

TB Intensive San Antonio, Texas November 11 14, 2014

Making the Diagnosis of Tuberculosis

Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

Grant Summary Report: Expansion of Nucleic Acid Amplification Testing for TB In Public Health Laboratories

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

Using Xpert to discontinue airborne isolation The Consensus Statement

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Annual Tuberculosis Report Oregon 2007

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

TB Contact Investigation

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

AFB Identification Texas Approach

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

Clinical Practice Guideline

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

2018 Tuberculosis Clinical Intensive: Infection Prevention & Control. > No disclosures

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Public Health Mycobacteriology (TB) Laboratory Testing Services

Revised National Tuberculosis Control Programme

Successful strategies for reporting TB results to public health officials. Max Salfinger, MD Mycobacteriology and Pharmacokinetics Denver, Colorado

Tuberculosis (TB) and Infection Control PICNET Conference April 12, 2013

TUBERCULOSIS. Pathogenesis and Transmission

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Utilizing All the Tools in the TB Toolbox

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Chapter 4 Diagnosis of Tuberculosis Disease

TB Infection Control. Delvina Mimi Ford, BSN, RN, CCRN-K, has the following disclosures to make:

TB Infection Control. Carol Staton, RN, BSN March 17, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Arizona Annual Tuberculosis Surveillance Report

TB Infection Control

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Infectious Diseases Society of America Emerging Infections Network. Comments for Query: Diagnostic Testing for Mycobacterium tuberculosis

TB BASICS: PRIORITIES AND CLASSIFICATIONS

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

TB Clinical Guidelines: Revision Highlights March 2014

TB Program Management San Antonio, Texas November 5-7, 2008

Assessing the programmatic management of drug-resistant TB

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Diagnosis and Treatment of Tuberculosis, 2011

TB Updates for the Physician Rochester, Minnesota June 19, 2009

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory

Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective

Contact Investigation San Antonio, Texas January 14-15, 2013

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

C. Difficile Testing Protocol

Standardized Case Definition for Extrapulmonary Nontuberculous Mycobacteria Infections

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Role of the Laboratory in TB Diagnosis and Management

Haley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic

Diagnosis of Extra Pulmonary Tuberculosis By Using Xpert MTB/RIF Assay (CBNAAT) And MGIT Liquid Culture.

National TB Services Survey Report

Contact Investigation Salina, Kansas

Clarithromycin-resistant Mycobacterium Shinjukuense Lung Disease: Case Report and Literature Review

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

New Standards for an Old Disease:

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

How best to structure a laboratory network with new technologies

TB in Corrections Phoenix, Arizona

The diagnosis of active TB

TUBERCULOSIS CONTACT INVESTIGATION

Andrew Ramsay Secretary STP Working Group on New Diagnostics WHO/TDR 20, Avenue Appia CH-1211, Geneva 27, Switzerland

A Clinician s Guide to the TB Laboratory

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

TB Contact Investigation Basics

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Tuberculosis Intensive

Transcription:

Nucleic Acid Amplification Test for Tuberculosis Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

What is this test? Nucleic Acid Amplification Test (NAAT) identifies genetic material unique to MTB Several NAA test have been FDA approved 1995-Amplified Mycobacterium tuberculosis Direct Test (MTD, Gen-Probe, San Diego, California) was FDA approved in for AFB smear-positive respiratory specimens 1999-An enhanced test (MTD-2) was approved for AFB smear-negative respiratory specimens. Oregon State Public Health Lab (OSPHL) will utilize Gen Probe MTD-2 NAAT is also referred to as Polymerase Chain Reaction (PCR) test.

Why is NAAT so great? TB genetic material can be detected using NAAT within 3-5 hours while cultures take weeks! Find out faster if smear+ is TB vs. NTM (save time and money on drugs, contact investigation, etc) Earlier diagnosis for smear- (less delayed diagnosis and TB transmission, decrease the inappropriate use of fluoroquinolones) It s easy (no extra sputum needed)! It s free for LHDs!

How will this work for LHDs? Collect sputum to rule out TB and send to lab as usual OSPHL will test the first sputum with NAAT If the first sputum is smear-/naat -, but a subsequent sputum is smear+ that specimen should also get tested. Others tested by special request only If you do not want sputum tested, indicate on lab slip

How do private providers order NAAT? Processed sediments may be sent to OSPHL directly from the lab or hospital There will be a charge of $40.00 for testing The provider should contact OSPHL at 503-693-4100 or see OSPHL web site for further instruction.

When should NAAT not be used? Do not use if patient has taken TB medications in the past 12 months (not a test of cure, not for previously treated B waivers) Can detect nucleic acids from dead and live organisms, so may remain positive long after treatment is completed and the culture is negative Do not use if patient has taken TB medications for more than 7 days Do not use if low suspicion of TB (example, B waiver). Positive predictive value of the NAA test is <50%

What is NAAT MTD-2 FDA approved for? Smear+ sputum specimens Smear- sputum specimens Patients who haven t received TB treatment Patients who are highly suspected to have TB Isn t approved for non-respiratory specimens, but there may be clinical utility in using test Further research needed on using for children who cannot produce sputum (gastric aspirates)

How good is this test? Respiratory smear+ specimens from untreated patients with high suspicion for TB. Sensitivity=95%, Specificity=98% Respiratory smear- specimens from untreated patients with high suspicion for TB. Sensitivity=66%, Specificity=98%

How good is NAAT continued Good test for smear+ Sensitivity for smear- is low (66%) A test with high sensitivity catches all people with a disease. If test has low sensitivity, may believe patient does not have disease when they do (a false negative) MTD-2 detects only 50%--80% of AFB smearnegative, culture-positive pulmonary TB cases

Interpretation of Results Not a perfect test. Does not replace culture results which are the gold standard. Interpret within the context of the patient s symptoms, chest x-ray, smear and culture

Smear+, NAAT+ Presume active TB disease Start contact investigation Start TB medication Keep in isolation until cleared Confirm by culture result

Smear+, NAAT- Suspect nontuberculous mycobacterium (NTM). Does not rule out TB Consider delaying treatment, contact investigation and removing from isolation. But if highly suspected of TB or lives in congregate setting or with high risk individuals request a second NAAT. Confirm findings with culture result

Smear-, NAAT+ Likely has active TB disease Consider submitting another specimen for NAAT to verify Presumed to have TB if two or more specimens are NAAT positive Use clinical judgment to determine whether to start treatment, start contact investigation and place on isolation. Confirm by culture result

Smear-, NAAT- For smear- specimens, sensitivity is low Diagnosis of TB cannot be excluded Rely on clinical judgment Requesting a second NAAT may be helpful Contact investigation may be delayed and patient considered non-infectious if sputum smear- x 2 and all NAAT results are negative. Confirm by culture result

Inhibited NAAT Amplification was inhibited due to a naturally occurring inhibitor in the specimen or processing reagent (example: blood). Can result in a false negative Test for inhibitors will be automatically run by lab on all smear+, NAAT- specimens If present, lab will contact you for additional specimen to test

Conclusion

Conclusion NAAT will provide LHDs with additional information to base decisions upon LHDs will not need to do anything different when collecting sputum to rule out TB Do not use NAAT if the patient has been on TB meds. for more than 7 days or was treated within last year The TB Program is available to assist with interpretation of results!

Resources State summary: http://www.oregon.gov/dhs/ph/tb/tools/n AATguide.pdf OSPHL: http://oregon.gov/dhs/ph/phl/docs/guide.p df CDC: http://www.cdc.gov/mmwr/preview/mmwrht ml/mm5801a3.htm?s_cid=mm5801a3_e